Elevated RBP-Jκ and CXCL11 Expression in Colon Cancer is Associated with an Unfavorable Clinical Outcome

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.2155130620402
   PubMed Web of Science ®Google Scholar
• Tanigaki K, Honjo T. Two opposing roles of RBP-J in Notch signaling. Curr Top Dev Biol. 2010;92:231–252.20816397
   PubMed Web of Science ®Google Scholar
• Raafat A, Bargo S, McCurdy D, Callahan R. The ANK repeats of Notch-4/Int3 activate NF-κB canonical pathway in the absence of Rbpj and causes mammary tumorigenesis. Sci Rep. 2017;7(1):13690. doi:10.1038/s41598-017-13989-729057904
   PubMed Web of Science ®Google Scholar
• Meurette O, Mehlen P. Notch signaling in the tumor microenvironment. Cancer Cell. 2018;34(4):536–548. doi:10.1016/j.ccell.2018.07.00930146333
   PubMed Web of Science ®Google Scholar
• van Es JH, van Gijn ME, Riccio O, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435(7044):959–963. doi:10.1038/nature0365915959515
   PubMed Web of Science ®Google Scholar
• Yong T, Sun A, Henry MD, Meyers S, Davis JN. Down regulation of CSL activity inhibits cell proliferation in prostate and breast cancer cells. J Cell Biochem. 2011;112(9):2340–2351. doi:10.1002/jcb.2315721520243
   PubMed Web of Science ®Google Scholar
• Li JY, Huang WX, Zhou X, Chen J, Li Z. Numb inhibits epithelial-mesenchymal transition via RBP-Jκ-dependent Notch1/PTEN/FAK signaling pathway in tongue cancer. BMC Cancer. 2019;19(1):391. doi:10.1186/s12885-019-5605-531023264
   PubMed Web of Science ®Google Scholar
• Chow MT, Luster AD. Chemokines in cancer. Cancer Immunol Res. 2014;2(12):1125–1131. doi:10.1158/2326-6066.CIR-14-016025480554
   PubMed Web of Science ®Google Scholar
• Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572. doi:10.1038/nri.2017.4928555670
   PubMed Web of Science ®Google Scholar
• Puchert M, Obst J, Koch C, Zieger K, Engele J. CXCL11 promotes tumor progression by the biased use of the chemokine receptors CXCR3 and CXCR7. Cytokine. 2020;125:154809. doi:10.1016/j.cyto.2019.15480931437604
   PubMed Web of Science ®Google Scholar
• Gao Q, Wang S, Chen X, et al. Cancer-cell-secreted CXCL11 promoted CD8(+) T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC. J Immunother Cancer. 2019;7(1):42. doi:10.1186/s40425-019-0511-630744691
   PubMed Web of Science ®Google Scholar
• Tokunaga R, Zhang W, Naseem M, et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev. 2018;63:40–47. doi:10.1016/j.ctrv.2017.11.00729207310
   PubMed Web of Science ®Google Scholar
• Chu D, Zheng J, Wang W, et al. Notch2 expression is decreased in colorectal cancer and related to tumor differentiation status. Ann Surg Oncol. 2009;16(12):3259–3266. doi:10.1245/s10434-009-0655-619653042
   PubMed Web of Science ®Google Scholar
• Aster JC, Pear WS, Blacklow SC. The varied roles of notch in cancer. Annu Rev Pathol. 2017;12:245–275. doi:10.1146/annurev-pathol-052016-10012727959635
   PubMed Web of Science ®Google Scholar
• Vinson KE, George DC, Fender AW, et al. The Notch pathway in colorectal cancer. Int J Cancer. 2016;138(8):1835–1842. doi:10.1002/ijc.2980026264352
   PubMed Web of Science ®Google Scholar
• VanDussen KL, Carulli AJ, Keeley TM, et al. Notch signaling modulates proliferation and differentiation of intestinal crypt base columnar stem cells. Development. 2012;139(3):488–497. doi:10.1242/dev.07076322190634
   PubMed Web of Science ®Google Scholar
• Braune EB, Tsoi YL, Phoon YP, et al. Loss of CSL unlocks a hypoxic response and enhanced tumor growth potential in breast cancer cells. Stem Cell Rep. 2016;6(5):643–651. doi:10.1016/j.stemcr.2016.03.004
   PubMed Web of Science ®Google Scholar
• Chen X, Thiaville MM, Chen L, et al. Defining NOTCH3 target genes in ovarian cancer. Cancer Res. 2012;72(9):2294–2303. doi:10.1158/0008-5472.CAN-11-218122396495
   PubMed Web of Science ®Google Scholar
• Hu XB, Feng F, Wang YC, et al. Blockade of notch signaling in tumor-bearing mice may lead to tumor regression, progression, or metastasis, depending on tumor cell types. Neoplasia. 2009;11(1):32–38. doi:10.1593/neo.8100819107229
   PubMed Web of Science ®Google Scholar
• Liu B, Lin X, Yang X, et al. Downregulation of RND3/RhoE in glioblastoma patients promotes tumorigenesis through augmentation of notch transcriptional complex activity. Cancer Med. 2015;4(9):1404–1416. doi:10.1002/cam4.48426108681
   PubMed Web of Science ®Google Scholar
• Lv Q, Shen R, Wang J. RBPJ inhibition impairs the growth of lung cancer. Tumour Biol. 2015;36(5):3751–3756. doi:10.1007/s13277-014-3015-525589461
   PubMedGoogle Scholar
• Avila JL, Kissil JL. Notch signaling in pancreatic cancer: oncogene or tumor suppressor? Trends Mol Med. 2013;19(5):320–327. doi:10.1016/j.molmed.2013.03.00323545339
   PubMed Web of Science ®Google Scholar
• Nagao H, Setoguchi T, Kitamoto S, et al. RBPJ is a novel target for rhabdomyosarcoma therapy. PLoS One. 2012;7(7):e39268. doi:10.1371/journal.pone.003926822792167
   PubMed Web of Science ®Google Scholar
• Thierry GR, Gentek R, Bajenoff M. Remodeling of reactive lymph nodes: dynamics of stromal cells and underlying chemokine signaling. Immunol Rev. 2019;289(1):42–61. doi:10.1111/imr.1275030977194
   PubMed Web of Science ®Google Scholar
• Li X, Wang M, Gong T, et al. A S100A14-CCL2/CXCL5 signaling axis drives breast cancer metastasis. Theranostics. 2020;10(13):5687–5703. doi:10.7150/thno.4208732483412
   PubMed Web of Science ®Google Scholar
• Nazari A, Ahmadi Z, Hassanshahi G, et al. Effective treatments for bladder cancer affecting CXCL9/CXCL10/CXCL11/CXCR3 axis: a review. Oman Med J. 2020;35(2):e103. doi:10.5001/omj.2020.2132181005
   PubMedGoogle Scholar
• Gao YJ, Liu L, Li S, et al. Down-regulation of CXCL11 inhibits colorectal cancer cell growth and epithelial-mesenchymal transition. Onco Targets Ther. 2018;11:7333–7343. doi:10.2147/OTT.S16787230425523
   PubMed Web of Science ®Google Scholar
• Benhadjeba S, Edjekouane L, Sauvé K, Carmona E, Tremblay A. Feedback control of the CXCR7/CXCL11 chemokine axis by estrogen receptor α in ovarian cancer. Mol Oncol. 2018;12(10):1689–1705. doi:10.1002/1878-0261.1236230051594
   PubMed Web of Science ®Google Scholar
• Liubomirski Y, Lerrer S, Meshel T, et al. Notch-mediated tumor-stroma-inflammation networks promote invasive properties and CXCL8 expression in triple-negative breast cancer. Front Immunol. 2019;10:804. doi:10.3389/fimmu.2019.0080431105691
   PubMed Web of Science ®Google Scholar
• Azizidoost S, Asnafi AA, Saki N. Signaling-chemokine axis network in brain as a sanctuary site for metastasis. J Cell Physiol. 2019;234(4):3376–3382. doi:10.1002/jcp.2730530187487
   PubMed Web of Science ®Google Scholar
• Ibrahim SA, Gadalla R, El-Ghonaimy EA, et al. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways. Mol Cancer. 2017;16(1):57. doi:10.1186/s12943-017-0621-z28270211
   PubMed Web of Science ®Google Scholar
• Chen H, Edwards R, Tucci S, et al. Chemokine 25-induced signaling suppresses colon cancer invasion and metastasis. J Clin Invest. 2012;122(9):3184–3196. doi:10.1172/JCI6211022863617
   PubMed Web of Science ®Google Scholar
• Procopio MG, Laszlo C, Al Labban D, et al. Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation. Nat Cell Biol. 2015;17(9):1193–1204.26302407
   PubMed Web of Science ®Google Scholar
• Wang WJ, Yao Y, Jiang LL, et al. Knockdown of lymphoid enhancer factor 1 inhibits colon cancer progression in vitro and in vivo. PLoS One. 2013;8(10):e76596. doi:10.1371/journal.pone.007659624098538
   PubMed Web of Science ®Google Scholar
• Maciaczyk D, Picard D, Zhao L, et al. CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells. Br J Cancer. 2017;117(1):102–112. doi:10.1038/bjc.2017.15728571041
   PubMed Web of Science ®Google Scholar
• Al Labban D, Jo SH, Ostano P, et al. Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B. J Clin Invest. 2018;128(6):2581–2599. doi:10.1172/JCI9691529757189
   PubMed Web of Science ®Google Scholar